7DCX

S-3C1-F3a structure, two RBDs are up and one RBD is down, each RBD binds with a 3C1 fab.

7DCX の概要

• エントリーDOI: 10.2210/pdb7dcx/pdb
• EMDBエントリー: 30641
• 分子名称: The heavy chain of 3C1 fab that binds with the up RBD, Spike glycoprotein, The light chain of 3C1 fab (3 entities in total)
• 機能のキーワード: viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV); 詳細
• タンパク質・核酸の鎖数: 9
• 化学式量合計: 564297.06

構造登録者

Cong, Y.,Liu, C.X. (登録日: 2020-10-27, 公開日: 2020-12-02, 最終更新日: 2024-10-30)

主引用文献

Zhang, C.,Wang, Y.,Zhu, Y.,Liu, C.,Gu, C.,Xu, S.,Wang, Y.,Zhou, Y.,Wang, Y.,Han, W.,Hong, X.,Yang, Y.,Zhang, X.,Wang, T.,Xu, C.,Hong, Q.,Wang, S.,Zhao, Q.,Qiao, W.,Zang, J.,Kong, L.,Wang, F.,Wang, H.,Qu, D.,Lavillette, D.,Tang, H.,Deng, Q.,Xie, Y.,Cong, Y.,Huang, Z.
Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
Nat Commun, 12:264-264, 2021

PubMed Abstract: The ongoing pandemic of coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neutralizing antibodies against SARS-CoV-2 are an option for drug development for treating COVID-19. Here, we report the identification and characterization of two groups of mouse neutralizing monoclonal antibodies (MAbs) targeting the receptor-binding domain (RBD) on the SARS-CoV-2 spike (S) protein. MAbs 2H2 and 3C1, representing the two antibody groups, respectively, bind distinct epitopes and are compatible in formulating a noncompeting antibody cocktail. A humanized version of the 2H2/3C1 cocktail is found to potently neutralize authentic SARS-CoV-2 infection in vitro with half inhibitory concentration (IC50) of 12 ng/mL and effectively treat SARS-CoV-2-infected mice even when administered at as late as 24 h post-infection. We determine an ensemble of cryo-EM structures of 2H2 or 3C1 Fab in complex with the S trimer up to 3.8 Å resolution, revealing the conformational space of the antigen-antibody complexes and MAb-triggered stepwise allosteric rearrangements of the S trimer, delineating a previously uncharacterized dynamic process of coordinated binding of neutralizing antibodies to the trimeric S protein. Our findings provide important information for the development of MAb-based drugs for preventing and treating SARS-CoV-2 infections.

PubMed: 33431876
DOI: 10.1038/s41467-020-20465-w

実験手法

ELECTRON MICROSCOPY (5.9 Å)